Market Overview:
The global mycosis fungoides therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of mycosis fungoides, rising awareness about mycosis fungoides, and technological advancements in the field of mycosis fungoides therapeutics. The global mycosis fungoides therapeutics market is segmented on the basis of type into small molecules and biologics. On the basis of application, the market is segmented into hospital, clinic, and other applications. The hospital segment is expected to account for a major share of the global mycosis fungoids therapeutics market during the forecast period owing to increased prevalence of cancer patients across hospitals worldwide.
Product Definition:
Mycosis Fungoides Therapeutics is a term that refers to the use of drugs or other treatments to cure mycosis fungoides, which is a type of cancer that affects the skin.
Small Molecules:
Small molecules are the most basic and common type of drug used for the treatment of diseases. They can be extracted from plants or animals, but they all have four basic characteristics in common; they are organic compounds, they can fit into a cell without causing harm, there is a natural tendency towards them by the body’s own mechanism (metabolism), and lastly if taken in appropriate quantities will provide health benefits to humans.
Biologics:
Biologics are living organisms or medicines derived from living organisms and used to treat diseases. Biologics are different from synthetic (chemical-based) drugs as they are based on the biological mechanisms of action. They work by stimulating or blocking particular biochemical pathways that lead to the disease condition.
Application Insights:
The other application segment held the largest share of more than 60.0% in 2017. This is owing to the increasing prevalence of chronic mycoses and growing awareness among patients about available treatment options. In addition, a rise in number of research initiatives by key companies for developing new molecules for clinical trials will boost market growth over the forecast period.
Clinic-based mycosis fungoides therapeutics accounted for a significant share in 2017 due to rising incidence rates of this disease coupled with high awareness levels among healthcare professionals regarding available treatment options and their effectiveness. Moreover, an increase in funding opportunities by government bodies and non-profit organizations will further propel market growth over the forecast period as these entities support promising research projects related to CMTs at universities or institutes level across the globe.
Regional Analysis:
North America dominated the global mycosis fungoides therapeutics market with a share of 59.1% in 2017. This is attributed to the local presence of key players, high adoption rate for new treatment methods, and availability of reimbursement facilities in this region. The U.S.-based companies are engaged in extensive R&D activities to develop novel drugs targeting MDR/MIP-2 proteins for the treatment of skin cancers and other diseases caused by these proteins such as dermatomycoses and systemic fungal infections (SFIs).
Growth Factors:
- Increasing incidence of mycosis fungoides
- Growing awareness about mycosis fungoides and its treatment options
- Rising demand for better and more effective therapies for mycosis fungoides
- Availability of novel therapeutics for the treatment of mycosis fungoides
- Growing investment in research and development for the development of new therapies for mycosis fungoids
Scope Of The Report
Report Attributes
Report Details
Report Title
Mycosis Fungoides Therapeutics Market Research Report
By Type
Small Molecules, Biologics
By Application
Hospital, Clinic, Other
By Companies
Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., Takeda Pharmaceutical Co. Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Mycosis Fungoides Therapeutics Market Report Segments:
The global Mycosis Fungoides Therapeutics market is segmented on the basis of:
Types
Small Molecules, Biologics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Azurity Pharmaceuticals Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- Seattle Genetics Inc.
- Soligenix Inc.
- Takeda Pharmaceutical Co. Ltd.
Highlights of The Mycosis Fungoides Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Small Molecules
- Biologics
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mycosis Fungoides Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mycosis fungoides therapeutics is a company that develops and manufactures drugs to treat mycosis fungoides, a type of skin cancer. Mycosis fungoides therapeutics' main product is imatinib mesylate, which it markets under the brand name Gleevec.
Some of the key players operating in the mycosis fungoides therapeutics market are Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., Takeda Pharmaceutical Co. Ltd..
The mycosis fungoides therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mycosis Fungoides Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mycosis Fungoides Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mycosis Fungoides Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mycosis Fungoides Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mycosis Fungoides Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Mycosis Fungoides Therapeutics Market Size and Y-o-Y Growth
4.5.2 Mycosis Fungoides Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Mycosis Fungoides Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mycosis Fungoides Therapeutics Market Size Forecast by Type
5.2.1 Small Molecules
5.2.2 Biologics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mycosis Fungoides Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mycosis Fungoides Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mycosis Fungoides Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mycosis Fungoides Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mycosis Fungoides Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Mycosis Fungoides Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mycosis Fungoides Therapeutics Market Size Forecast by Type
9.6.1 Small Molecules
9.6.2 Biologics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mycosis Fungoides Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mycosis Fungoides Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Mycosis Fungoides Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mycosis Fungoides Therapeutics Market Size Forecast by Type
10.6.1 Small Molecules
10.6.2 Biologics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mycosis Fungoides Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mycosis Fungoides Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mycosis Fungoides Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mycosis Fungoides Therapeutics Market Size Forecast by Type
11.6.1 Small Molecules
11.6.2 Biologics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mycosis Fungoides Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mycosis Fungoides Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Mycosis Fungoides Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mycosis Fungoides Therapeutics Market Size Forecast by Type
12.6.1 Small Molecules
12.6.2 Biologics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mycosis Fungoides Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mycosis Fungoides Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mycosis Fungoides Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mycosis Fungoides Therapeutics Market Size Forecast by Type
13.6.1 Small Molecules
13.6.2 Biologics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mycosis Fungoides Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mycosis Fungoides Therapeutics Market: Competitive Dashboard
14.2 Global Mycosis Fungoides Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Azurity Pharmaceuticals Inc.
14.3.2 Celgene Corp.
14.3.3 Eisai Co. Ltd.
14.3.4 Helsinn Healthcare SA
14.3.5 Horizon Therapeutics Plc
14.3.6 Kyowa Kirin Co. Ltd.
14.3.7 Merck & Co. Inc.
14.3.8 Seattle Genetics Inc.
14.3.9 Soligenix Inc.
14.3.10 Takeda Pharmaceutical Co. Ltd.
